دورية أكاديمية
Cytogenetics in Chronic Lymphocytic Leukemia : ERIC Perspectives and Recommendations
| العنوان: | Cytogenetics in Chronic Lymphocytic Leukemia : ERIC Perspectives and Recommendations |
|---|---|
| المؤلفون: | Baliakas, Panagiotis, Espinet, Blanca, Mellink, Clemens, Jarosova, Marie, Athanasiadou, Anastasia, Ghia, Paolo, Kater, Arnon P., Oscier, David, Haferlach, Claudia, Stamatopoulos, Kostas |
| بيانات النشر: | Uppsala universitet, Science for Life Laboratory, SciLifeLab Uppsala universitet, Experimentell och klinisk onkologi Uppsala Univ Hosp, Dept Clin Genet, Uppsala, Sweden. Hosp del Mar, Mol Cytogenet Lab, Pathol Dept, Barcelona, Spain.;Inst Hosp del Mar Invest Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain. Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Clin Genet, Genom Lab, Amsterdam, Netherlands. Masaryk Univ, Fac Med, Inst Med Genet & Genom, Brno, Czech Republic.;Univ Hosp Brno, Brno, Czech Republic.;Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.;Masaryk Univ, Fac Med, Brno, Czech Republic. G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece.;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece. IRCCS Osped San Raffaele, Div Expt Oncol, CLL & BCell Neoplasia Unit, Strateg Res Program, Milan, Italy.;Univ Vita Salute San Raffaele, Milan, Italy. Univ Amsterdam, Amsterdam Univ Med Ctr, Lymphoma & Myeloma Ctr Amsterdam, Dept Hematol,Canc Ctr Amsterdam, Amsterdam, Netherlands. Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England. MLL Munich Leukemia Lab, Munich, Germany. Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece.;Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2022 |
| المجموعة: | Uppsala University: Publications (DiVA) |
| مصطلحات موضوعية: | Hematology, Hematologi, Cancer and Oncology, Cancer och onkologi |
| الوصف: | Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | HemaSphere, 2022, 6:4; orcid:0000-0002-5634-7156; http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-472929Test; PMID 35392482; ISI:000776250000005 |
| DOI: | 10.1097/HS9.0000000000000707 |
| الإتاحة: | https://doi.org/10.1097/HS9.0000000000000707Test http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-472929Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.877DDCA7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/HS9.0000000000000707 |
|---|